Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.

ABSTRACT: Chronic myeloid leukemia (CML) is characterized by the accumulation of malignant and immature white blood cells which spread to the peripheral blood and other tissues/organs. Despite the fact that current tyrosine kinase inhibitors (TKIs) are capable of achieving the complete remission by reducing the tumor burden, severe adverse effects often occur in CML patients treated with TKIs. The differentiation therapy exhibits therapeutic potential to improve cure rates in leukemia, as evidenced by the striking success of all-trans-retinoic acid in acute promyelocytic leukemia treatment. However, there is still a lack of efficient differentiation therapy strategy in CML. Here we showed that MPL, which encodes the thrombopoietin receptor driving the development of hematopoietic stem/progenitor cel

SUBMITTER: Zuo S 

PROVIDER: S-EPMC7904926 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature